VLA 0.00% $1.75 viralytics limited

Phase 2, Phase 3, Phase 4, page-28

  1. 245 Posts.
    lightbulb Created with Sketch. 20

    I'm pretty sure that it would not be in Merck's best interest to present anything from the STORM/KEYNOTE trial. Why give a leg-up to potential bidders / competitors ? Merck will be keen to keep all of the results hushed up until they are prepared to licence/partner/acquire the technology if the trial is successful.

    .
 
watchlist Created with Sketch. Add VLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.